Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Endocrinology

Building Your Care Team and Long-Term Monitoring

At a Glance

People with hyperinsulinism due to INSR deficiency often need coordinated, lifelong follow-up because high insulin and changing blood sugar can affect the heart, kidneys, eyes, teeth, reproductive health, and emotional well-being. Screening should be tailored by an endocrinologist.

Managing an INSR-related syndrome is a lifelong journey that extends far beyond controlling blood sugar. Because insulin receptors are located throughout the body—in the heart, kidneys, skin, and eyes—the condition can affect multiple organ systems over time [1][2]. Long-term health depends on a coordinated, multidisciplinary care team that monitors for complications.

Your Multidisciplinary Care Team

Because this condition is so rare, you will likely need a team of specialists who communicate regularly. This “medical home” approach ensures that treatment for one symptom doesn’t accidentally worsen another [3][4].

  • Pediatric/Adult Endocrinologist: The “quarterback” of your team who manages blood sugar, growth, and hormone balance [5].
  • Cardiologist: Monitors for heart muscle changes, specifically hypertrophic cardiomyopathy (thickening of the heart walls) [6].
  • Nephrologist: Tracks kidney health and screens for nephrocalcinosis (calcium deposits in the kidneys) [7].
  • Ophthalmologist: Conducts dilated eye exams to check for retinopathy (damage to the blood vessels in the retina) [8].
  • Registered Dietitian: Helps balance complex carbohydrate intake to prevent both high and low blood sugars [9].
  • Genetic Counselor: Provides guidance on the inheritance of the mutation and what it means for other family members [10].
  • Psychologist/Social Worker: Supports the emotional and mental health of the patient and their caregivers [11].

Essential Long-Term Surveillance

Not every patient needs every specialist or test. Screening should be risk-based depending on your specific clinical presentation, as directed by your endocrinologist.

The Heart: Hypertrophic Cardiomyopathy

In severe forms like Donohue and Rabson-Mendenhall, the heart can become thickened because it is exposed to extremely high levels of insulin, which acts like a growth signal [6][12].

  • What to watch for: Rapid breathing, excessive sweating during feeding, or poor weight gain [13].
  • Monitoring: Baseline echocardiogram (heart ultrasound), with follow-ups as recommended by a cardiologist, is especially relevant for severe phenotypes [6][14].

The Kidneys: Nephrocalcinosis

High insulin levels can change how the kidneys handle minerals, potentially leading to nephrocalcinosis [15].

  • Monitoring: Absence of symptoms (like normal blood pressure or no blood in urine) does not reassure that nephrocalcinosis is absent, as it can be asymptomatic [5]. Screening relies on clinician-directed blood pressure measurement, renal function tests/urinalysis, and periodic renal ultrasounds [7][16].

The Eyes: Retinopathy

If the condition progresses to diabetes, the small blood vessels in the eyes are at risk.

  • A Unique Warning: If a patient has established diabetic retinopathy, a very rapid improvement in blood sugar levels can occasionally trigger or worsen proliferative retinopathy [8].
  • Monitoring: Annual dilated eye exams are standard once diabetes is diagnosed, and patients should work closely with their ophthalmologist during major treatment changes [8][17].

Dental and Reproductive Health

  • Dental Care: Patients with intermediate or severe phenotypes often experience early tooth eruption or gum overgrowth (gingival hyperplasia). Frequent dental cleanings and early intervention are essential [18][19].
  • Reproductive Health: For those with Type A, monitoring for hyperandrogenism (excess hormones) is key to managing symptoms like acne, hair growth, and irregular periods [20][21].

The Psychosocial Toll

The burden of managing a rare, complex metabolic disorder can be heavy. Families often report “diagnostic odyssey” fatigue—having to explain the condition to every new doctor they meet [22].

  • Body Image and Stigma: Skin changes like acanthosis nigricans or physical growth differences can impact self-esteem, especially during adolescence [23][24].
  • Caregiver Stress: The 24/7 nature of monitoring for hypoglycemia can lead to significant sleep deprivation and anxiety for parents [25].
  • Support is Essential: Psychological support is not an “extra”—it is a core part of the treatment plan. Connecting with rare-disease communities and working with therapists familiar with chronic illness can help families build resilience [26][11].

Common questions in this guide

Which specialists are usually part of an INSR deficiency care team?
Care commonly involves an endocrinologist coordinating with cardiology, nephrology, ophthalmology, a registered dietitian, genetics, dental care, and mental-health support as needed. The exact team depends on the person’s age, symptoms, and specific form of the condition.
What long-term screening may be needed with hyperinsulinism due to INSR deficiency?
Screening is individualized and may include a heart ultrasound, blood pressure checks, kidney function tests, urine testing, and kidney ultrasounds. Dilated eye exams are generally important after diabetes develops, while dental, reproductive, and emotional health should also be monitored when relevant.
Why is heart monitoring important in severe INSR deficiency?
Very high insulin levels can act as a growth signal and may cause the heart muscle to become thickened in severe forms of the condition. A cardiologist may recommend a baseline heart ultrasound and follow-up exams, especially if rapid breathing, sweating during feeding, or poor weight gain occurs.
How are kidney complications monitored in INSR deficiency?
Nephrocalcinosis, or calcium deposits in the kidneys, can occur without obvious symptoms. Clinician-directed monitoring may include blood pressure measurement, kidney function tests, urine testing, and periodic kidney ultrasounds.
When should a person with INSR deficiency have eye exams?
Once diabetes is diagnosed, annual dilated eye exams are commonly used to check for damage to the retinal blood vessels. People with existing diabetic retinopathy should work closely with an eye specialist during major blood sugar treatment changes because rapid improvement can sometimes worsen proliferative retinopathy.
What support can help families cope with INSR deficiency?
A therapist or psychologist familiar with chronic illness can help patients and caregivers manage anxiety, sleep loss, body-image concerns, and daily treatment stress. Rare-disease support communities may also help families find practical information and emotional connection.

Get notified when new evidence is published on Hyperinsulinism due to INSR deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    Hyperinsulinemic hypoglycemia due to pathogenic INSR variants: metabolic signature, phenotypic overlap, and semidominant inheritance.

    Marcelino do Nascimento R, Dos Santos A, Guadagnini D, et al.

    Frontiers in endocrinology 2026; (17()):1716020 doi:10.3389/fendo.2026.1716020.

    PMID: 42181197
  2. 2

    A de novo INSR variant in Type A insulin resistance syndrome: familial investigation and genetic implications.

    Lin X, Xu ZY, Xie LJ, et al.

    Gene 2026; (979()):149934 doi:10.1016/j.gene.2025.149934.

    PMID: 41360184
  3. 3

    Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating.

    Nijim Y, Awni Y, Adawi A, Bowirrat A

    Medicine 2016; (95(6)):e2710 doi:10.1097/MD.0000000000002710.

    PMID: 26871809
  4. 4

    Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.

    Patni N, Chard C, Araújo-Vilar D, et al.

    Orphanet journal of rare diseases 2024; (19(1)):263 doi:10.1186/s13023-024-03245-3.

    PMID: 38992753
  5. 5

    Rabson-Mendenhall Syndrome in a brother-sister pair in Kuwait: Diagnosis and 5 year follow up.

    Al-Kandari H, Al-Abdulrazzaq D, Al-Jaser F, et al.

    Primary care diabetes 2021; (15(1)):175-177 doi:10.1016/j.pcd.2020.07.012.

    PMID: 32843252
  6. 6

    Hypertrophic cardiomyopathy in Donohue syndrome.

    Termote JU, Breur JM, de Vroede MA

    Cardiology in the young 2016; (26(4)):815-8 doi:10.1017/S1047951115002437.

    PMID: 26555333
  7. 7

    A Novel Mutation in the INSR Gene Causes Severe Insulin Resistance and Rabson-Mendenhall Syndrome in a Paraguayan Patient.

    Rojas Velazquez MN, Blanco F, Ayala-Lugo A, et al.

    International journal of molecular sciences 2024; (25(6)) doi:10.3390/ijms25063143.

    PMID: 38542117
  8. 8

    Case Report: Tirzepatide improves glycemic control in Rabson-Mendenhall syndrome.

    Araújo-Vilar D, Vela A, Castro AI, et al.

    Frontiers in endocrinology 2026; (17()):1945251 doi:10.3389/fendo.2026.1945251.

    PMID: 42729636
  9. 9

    Management challenges of Rabson Mendenhall syndrome in a resource limited country: a case report.

    Aftab S, Shaheen T, Asif R, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2022; (35(11)):1429-1432 doi:10.1515/jpem-2022-0214.

    PMID: 36106528
  10. 10

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  11. 11

    Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society.

    Lambadiari V, Bargiota A, Kanaka-Gantenbein C, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(6)):1008-1016 doi:10.1016/j.eprac.2026.02.014.

    PMID: 41713690
  12. 12

    Donohue syndrome: A review of literature, case series, and anesthetic considerations.

    Kirkwood A, Stuart G, Harding L

    Paediatric anaesthesia 2018; (28(1)):23-27 doi:10.1111/pan.13273.

    PMID: 29148123
  13. 13

    Syndrome of Congenital Insulin Resistance Caused by a Novel INSR Gene Mutation

    Rojek A, Wikiera B, Noczynska A, Niedziela M

    Journal of clinical research in pediatric endocrinology 2023; (15(3)):312-317 doi:10.4274/jcrpe.galenos.2021.2021.0256.

    PMID: 34965699
  14. 14

    Intrauterine Growth Restriction and Hypertrophic Cardiomyopathy as Prenatal Ultrasound Findings in a Case of Leprechaunism.

    Perge K, Massoud M, Gauthier-Moulinier H, et al.

    Molecular syndromology 2020; (11(4)):223-227 doi:10.1159/000509837.

    PMID: 33224016
  15. 15

    Gastrointestinal dysmotility and pancreatic insufficiency in 2 siblings with Donohue syndrome.

    Kostopoulou E, Shah P, Ahmad N, et al.

    Pediatric diabetes 2017; (18(8)):839-843 doi:10.1111/pedi.12483.

    PMID: 28004474
  16. 16

    Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function.

    Okawa MC, Cochran E, Lightbourne M, Brown RJ

    The Journal of clinical endocrinology and metabolism 2022; (107(3)):e1032-e1046 doi:10.1210/clinem/dgab782.

    PMID: 34718628
  17. 17

    Systemic Diseases and the Eye: A Translational Perspective on Diabetes.

    Capobianco M, Zeppieri M, Nicolosi SG, et al.

    Chronic diseases and translational medicine 2026; doi:10.1002/cdt3.70071.

    PMID: 42851999
  18. 18

    Rabson-Mendenhall Syndrome: Analysis of the Clinical Characteristics and Gene Mutations in 42 Patients.

    Gong W, Chen W, Dong J, Liao L

    Journal of the Endocrine Society 2024; (8(8)):bvae123 doi:10.1210/jendso/bvae123.

    PMID: 38957655
  19. 19

    Severe insulin resistance syndrome - A rare case report and review of literature.

    Joshi SR, Pendyala GS, Shah P, et al.

    National journal of maxillofacial surgery 2021; (12(1)):100-105 doi:10.4103/njms.NJMS_55_20.

    PMID: 34188410
  20. 20

    Comprehensive assessment of the genotype-phenotype spectrum and treatment for monoallelic insulin receptoropathy in a cohort of 505 people.

    Brown RJ, Xu J, Luan J, et al.

    Research square 2026; doi:10.21203/rs.3.rs-10884175/v1.

    PMID: 42856426
  21. 21

    Case report: Glycaemic management and pregnancy outcomes in a woman with an insulin receptor mutation, p.Met1180Lys.

    Crowley MT, Goulden E, Sanchez-Lechuga B, et al.

    Clinical diabetes and endocrinology 2024; (10(1)):5 doi:10.1186/s40842-024-00166-9.

    PMID: 38461278
  22. 22

    Patients' perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy.

    Mosbah H, Vatier C, Andriss B, et al.

    European journal of endocrinology 2024; (190(1)):23-33 doi:10.1093/ejendo/lvad169.

    PMID: 38128113
  23. 23

    "We're stuck with what we've got": The impact of lipodystrophy on body image.

    Adams C, Stears A, Savage D, Deaton C

    Journal of clinical nursing 2018; (27(9-10)):1958-1968 doi:10.1111/jocn.14342.

    PMID: 29516553
  24. 24

    Health-related Quality of Life, Social, and Psychological Well-Being of 109 Adult Patients With Genetic Lipodystrophy.

    Mosbah H, Vatier C, Andriss B, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(8)):e2532-e2543 doi:10.1210/clinem/dgae837.

    PMID: 39657019
  25. 25

    Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People

    Özen S, Akıncı B, Oral EA

    Journal of clinical research in pediatric endocrinology 2020; (12(1)):17-28 doi:10.4274/jcrpe.galenos.2019.2019.0124.

    PMID: 31434462
  26. 26

    Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.

    Zhong ZX, Harris J, Wilber E, et al.

    Clinical endocrinology 2022; (97(6)):755-762 doi:10.1111/cen.14806.

    PMID: 35920656

This information about care teams and long-term monitoring for INSR-related hyperinsulinism is for educational purposes only and does not constitute medical advice. Your endocrinologist and other specialists should tailor screening to your or your child’s specific health needs.

Guide contents Hyperinsulinism due to INSR deficiency
Research & Literature
05 Treatment and Daily Management